BioMed Partners

The firm invests from early-stage seed and start-up through expansion and late-stage growth. Its deal profile includes company creation around academic intellectual property, spin-offs from research institutions, and direct equity into more mature biotech platforms. This spans pre-clinical therapeutics to clinical-stage companies and commercial-stage medtech.

The firm leverages its Basel location, positioned within the Basel Area life sciences cluster that includes the University of Basel, ETH Zurich, and major pharmaceutical headquarters. Deal flow originates from academic research spin-offs, university technology transfer offices, and direct relationships with research hospitals. This proximity-driven model gives it early access to European life sciences innovation.

The firm concentrates on therapeutics, diagnostics, and medical technology, with additional activity in digital health. Its portfolio construction targets drug development platforms, precision medicine, and enabling technologies for healthcare delivery. It does not invest outside life sciences.

BioMed Partners operates as a private equity and venture capital asset manager, not a family office. It raises capital from external limited partners rather than managing a single-source wealth pool, focused entirely on life sciences investments across multiple venture stages.

The firm invests primarily in Switzerland, Germany, and neighboring European countries with established life sciences ecosystems. Its Basel base provides direct access to the Swiss biotech corridor, while its mandate extends to similar clusters across Western and Central Europe.